Albireo Pharma, Inc. (ALBO) financial statements (2021 and earlier)

Company profile

Business Address 10 POST OFFICE SQUARE
BOSTON, MA 02109
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments251279152151132143158
Cash and cash equivalents251279152151132143158
Other undisclosed current assets118881055
Total current assets:262287160158142148163
Noncurrent Assets
Property, plant and equipment0111111
Intangible assets, net (including goodwill)17171717171717
Goodwill17171717171717
Other noncurrent assets6666561
Total noncurrent assets:24242424232319
TOTAL ASSETS:286311184182165171182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24201614181211
Accounts payable5457534
Accrued liabilities19171281388
Other liabilities1111110
Total current liabilities:25211715191212
Noncurrent Liabilities
Long-term debt and lease obligation13109 440
Long-term debt, excluding current maturities10109    
Operating lease, liability4   440
Liabilities, other than long-term debt, including:4444440
Other liabilities444444 
Other undisclosed liabilities, other than long-term debt      0
Other undisclosed noncurrent liabilities62656449454952
Total noncurrent liabilities:79787854535752
Total liabilities:104999569727064
Stockholders' equity
Stockholders' equity attributable to parent1812128911393102118
Common stock0000000
Additional paid in capital456451294291246243241
Accumulated other comprehensive income (loss)(9)26136117
Accumulated deficit(267)(242)(211)(191)(159)(152)(130)
Total stockholders' equity:1812128911393102118
TOTAL LIABILITIES AND EQUITY:286311184182165171182

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:3222611
Operating expenses(24)(29)(20)(31)(16)(22)(17)
Operating loss:(21)(27)(18)(30)(10)(21)(15)
Nonoperating income (expense)11  (7)12  
Foreign currency transaction gain (loss), before tax11  (7)   
Income (loss) from continuing operations before equity method investments, income taxes:(11)(27)(18)(36)2(21)(15)
Other undisclosed loss from continuing operations before income taxes(26)   (5)  
Loss before gain (loss) on sale of properties:(37)(27)(18)(36)(3)(21)(15)
Other undisclosed net income (loss)12  5(4)  
Net loss:(25)(27)(18)(31)(8)(21)(15)
Other undisclosed net loss attributable to parent (4)(2)  (1)(1)
Net loss available to common stockholders, diluted:(25)(31)(21)(31)(8)(22)(17)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(25)(27)(18)(31)(8)(21)(15)
Other comprehensive income (loss)(11)(4)(7)6(4)4(0)
Comprehensive loss:(36)(31)(25)(25)(12)(17)(15)
Other undisclosed comprehensive loss, net of tax, attributable to parent (4)(2)  (1)(1)
Comprehensive loss, net of tax, attributable to parent:(36)(35)(27)(25)(12)(18)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: